Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer

Published:2015-07 Issue:7 Volume:10 Page:1067-1075
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Glubb Dylan M.,Paré-Brunet Laia,Jantus-Lewintre Eloisa,Jiang Chen,Crona Daniel,Etheridge Amy S.,Mirza Osman,Zhang Wei,Seiser Eric L.,Rzyman Witold,Jassem Jacek,Auman Todd,Hirsch Fred R.,Owzar Kouros,Camps Carlos,Dziadziuszko Rafal,Innocenti Federico

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer;Chansky;J Thorac Oncol,2009

2. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?;Subramanian;J Natl Cancer Inst,2010

3. Angiogenesis in cancer, vascular, rheumatoid and other disease;Folkman;Nat Med,1995

4. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

5. Role of angiogenesis in the pathogenesis of cancer;Hoff;Cancer Treat Rev,2012

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma;Journal of Translational Medicine;2024-04-04

2. Systematic Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma;2023-11-17

3. Single-Cell RNA Sequencing Unravels Distinct Tumor Microenvironment of Different Components of Lung Adenocarcinoma Featured as Mixed Ground-Glass Opacity;Frontiers in Immunology;2022-07-06

4. KDR genetic predictor of toxicities induced by sorafenib and regorafenib;The Pharmacogenomics Journal;2022-04-28

5. Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial;Therapeutic Advances in Medical Oncology;2022-01